Displaying drugs 14926 - 14950 of 15709 in total
SB220025
Experimental
1-Naphthyl-L-alanine
Experimental
3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
Ethadione
Experimental
Verubulin
Antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Investigational
MEM 1414
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Ilodecakin
Investigational
Porphobilinogen
Porphobilinogen is a pyrrole involved in porphyrin metabolism. It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.
Experimental
Matched Description: … It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme …
Ditiocarb
A chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.
Experimental
Matched Description: … A chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental …
PF-04634817
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
Matched Description: … investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and …
Ladarixin
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Investigational
Matched Description: … investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and …
DA-8031
DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).
Investigational
Matched Description: … -8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and …
BZL101
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Matched Description: … BZL101 targets diseased cells while leaving normal cells healthy and intact. …
Bemegride
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Experimental
Matched Description: … It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. …
Lorecivivint
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
Investigational
Matched Description: … Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and …
(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE
Experimental
4-(1H-IMIDAZOL-1-YL)PHENOL
Experimental
N-acetylsulfanilyl chloride
ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
Investigational
Fluoromisonidazole F-18
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and …
KAI-1455
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … hip replacement and may protect against renal injury associated with contrast media. ... may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Motexafin gadolinium
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
Investigational
Matched Description: … cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and …
Displaying drugs 14926 - 14950 of 15709 in total